XML 69 R40.htm IDEA: XBRL DOCUMENT
v3.20.4

Acquisition and Variable Interest Entity - Additional Information (Detail) $ in Thousands, ¥ in Millions |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | ---
Sep. 15, 2020 USD ($) | Sep. 15, 2020 CNY (¥) | Jul. 31, 2020 USD ($) | Jul. 31, 2020 CNY (¥) | Dec. 31, 2020 USD ($) | Dec. 31, 2020 CNY (¥)
Beijing Falikang Pharmaceutical Co. Ltd [Member] |  |  |  |  |  |
Acquisition And Variable Interest Entity [Line Items] |  |  |  |  |  |
Percentage of outstanding shares owned |  |  |  |  | 51.10% | 51.10%
Investment | $ |  |  |  |  | $ 2,825 |
Beijing Falikang Pharmaceutical Co. Ltd [Member] | Variable Interest Entity, Not Primary Beneficiary [Member] |  |  |  |  |  |
Acquisition And Variable Interest Entity [Line Items] |  |  |  |  |  |
Investment |  |  |  |  | 2,800 | ¥ 19.2
FibroGen Beijing [Member] | Beijing Falikang Pharmaceutical Co. Ltd [Member] |  |  |  |  |  |
Acquisition And Variable Interest Entity [Line Items] |  |  |  |  |  |
Percentage of outstanding shares acquired |  |  |  |  |  | 48.90%
Cash consideration |  |  |  |  | $ 1,400 | ¥ 8.9
Percentage of outstanding shares owned |  |  |  |  | 51.10% | 51.10%
Falikang's total registered capital | ¥ |  |  |  |  |  | ¥ 17.5
Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member] | FibroGen Beijing [Member] |  |  |  |  |  |
Acquisition And Variable Interest Entity [Line Items] |  |  |  |  |  |
Percentage of outstanding shares acquired |  |  |  | 100.00% |  |
Cash consideration |  |  | $ 2,100 | ¥ 15.0 |  |
Transaction costs | ¥ |  |  |  | 5.0 |  |
Acquisition costs |  |  | 400 | ¥ 2.5 |  |
Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member] | FibroGen Beijing [Member] | Acquired License [Member] |  |  |  |  |  |
Acquisition And Variable Interest Entity [Line Items] |  |  |  |  |  |
Entire purchase price | $ |  |  | $ 2,500 |  |  |
Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member] | FibroGen Beijing [Member] | AstraZeneca AB [Member] | Beijing Falikang Pharmaceutical Co. Ltd [Member] |  |  |  |  |  |
Acquisition And Variable Interest Entity [Line Items] |  |  |  |  |  |
Percentage of outstanding shares sold in exchange for cash consideration | 48.90% | 48.90% |  |  |  |
Cash consideration for exchange of outstanding shares | $ 1,000 | ¥ 7.3 |  |  |  |
Percentage of outstanding shares owned | 51.10% | 51.10% |  |  |  |

X
- Definition Acquisition and variable interest entity line items. + References No definition available. + Details
Name: | fgen_AcquisitionAndVariableInterestEntityLineItems
Namespace Prefix: | fgen_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity method investment additions. + References No definition available. + Details
Name: | fgen_EquityMethodInvestmentAdditions
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of outstanding shares of acquiree sold by acquirer. + References No definition available. + Details
Name: | fgen_PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer
Namespace Prefix: | fgen_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Percentage of voting equity interests acquired at the acquisition date in the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -URI http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460 + Details
Name: | us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of total capital as defined by regulatory framework. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 948 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 505 -Section 50 -Paragraph 1 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=117337116&loc=SL5958568-112826 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 948 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=6490092&loc=d3e47080-110998 + Details
Name: | us-gaap_Capital
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of the entity's equity method investment which has been sold. + References No definition available. + Details
Name: | us-gaap_EquityMethodInvestmentSoldCarryingAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(1) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 5A -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685 + Details
Name: | us-gaap_VariableInterestEntityOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=fgen_BeijingFalikangPharmaceuticalCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_FibroGenBeijingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=fgen_AcquiredLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=fgen_AstraZenecaABMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |